Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα(q) and Gα(11) and kill uveal melanoma cells

There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gα(q) or Gα(11). Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalizati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Biol Ther
Hauptverfasser: Booth, Laurence, Roberts, Jane L., Sander, Cindy, Lalani, Alshad S., Kirkwood, John M., Hancock, John F., Poklepovic, Andrew, Dent, Paul
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606002/
https://ncbi.nlm.nih.gov/pubmed/30571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1551747
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge